- | Elicio Therapeutic
Lymph node-targeted vaccine elicits COVID-19 protection in vivo
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.
- | Scynexis
Scynexis debuts Brexafemme
Scynexis is introducing Brexafemme (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the Food and Drug Administration to treat vulvovaginal candidiasis, commonly referred to as vaginal yeast infection.
- | DURECT
PharmaShots Interview: Durect’s James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021
In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment
- | Aptinyx
Treating the Brain to Address Long-Term Chronic Pain with Andy Kidd MD Aptinyx
Andy Kidd MD is the President and COO and soon to be CEO of Aptinyx. With a focus on Pain Awareness Month, Andy provides a view into the world of treating long-term chronic pain and the necessary innovations to treat the cause of chronic pain in conditions like diabetic peripheral neuropathy and fibromyalgia.
- | Recce Pharmaceuticals
PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds
In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.
- | AltruBio
AltruBio snags a CMO after pivot from oncology to immunology
AltruBio has signed a new chief medical officer, five months after a makeover that saw it change its name, its focus and its board.
- | Cardiff Oncology
Cardiff reveals early data on challenger to Amgen’s KRAS crown
Cardiff’s onvansertib is being trialed in a phase 1b/2 study in patients with metastatic colorectal cancer who have a mutation of the KRAS gene, according to a Wednesday release. The therapy is being combined with chemotherapy and Roche’s stalwart Avastin. Patients must have failed on chemotherapy and or/Avastin prior to entry in the trial.
- | IMV Inc.
The Search Intensifies for Cancer Treatments with Fewer Side Effects
Dorigo is principal investigator of a clinical trial of a new immunotherapy called maveropepimut-S. It’s being developed by IMV Inc., a pharmaceutical company focused on innovative immune cell activating approaches.
